Taysha Gene Therapies to Participate in Upcoming August Investor Conferences
08/01/2022 - 07:00 AM
BTIG Biotechnology Conference on August 8, 2022 at 12:00 pm ET
2022 Wedbush PacGrow Healthcare Virtual Conference on August 10, 2022 at 9:45 am ET
DALLAS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in panel discussions at the BTIG Biotechnology Conference on August 8th and the 2022 Wedbush PacGrow Healthcare Virtual Conference on August 10th .
A webcast of the panels will be available in the “Events & Media” section of the Taysha corporate website at https://ir.tayshagtx.com/news-events/events-presentations . Archived versions of the webcast will be available on the website for 90 days.
Conference Details: Event: BTIG Biotechnology Conference Topic: AAV Gene Therapies for CNS Disorders: Challenges and Opportunities Date: Monday August 8 Time: 12:00 pm ET Format: Panel discussion Participant: Suyash Prasad, MBBS, M.Sc., MRCP, MRCPCH, FFPM, Chief Medical Officer and Head of Research and Development Event: 2022 Wedbush PacGrow Healthcare Virtual Conference Topic: UltraOrphan: When You’re One in a Million Date: Wednesday, August 10 Time: 9:45 am ET Format: Panel discussion Participant: RA Session II, President, Founder and Chief Executive Officer
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com .
Company Contact: Kimberly Lee, D.O. Chief Corporate Affairs Officer Taysha Gene Therapiesklee@tayshagtx.com
Media Contact: Carolyn Hawley Evoke Canalecarolyn.hawley@evokegroup.com
Taysha Gene Therapies Inc
TSHA Rankings
#681 Ranked by Stock Gains
TSHA Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology
About TSHA
taysha gene therapies, inc., a gene therapy company, develops adeno-associated virus based gene therapies for the treatment of monogenic diseases of the central nervous system. it primarily develops tsha-101 for the treatment of gm2 gangliosidosis; tsha-118 for the treatment of cln1 disease; tsha-102 for the treatment of rett syndrome; tsha-103 for the treatment of slc6a1 haploinsufficiency disorder; and tsha-104 for the treatment for surfeit locus 1 deficiency. the company also has strategic partnership with the university of texas southwestern medical center to develop and commercialize transformative gene therapy treatments. taysha gene therapies, inc. was founded in 2019 and is based in dallas, texas.